Moderna, Inc. (MRNA) Stock
Moderna stock price chart
MRNA stock quote & key statistics
Moderna annual financials
Income statement →| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2025 | $1.94B | -$2.82B | -$7.27 |
| FY2024 | $3.20B | -$3.56B | -$9.28 |
| FY2023 | $6.85B | -$4.71B | -$12.41 |
| FY2022 | $18.88B | $8.36B | $19.96 |
| FY2021 | $17.74B | $12.20B | $28.29 |
Fiscal year ending December 31. Source: company filings via EODHD.
About Moderna, Inc.
Moderna, Inc., based in Cambridge, Massachusetts, is a trailblazing biotechnology company specializing in the development and commercialization of messenger RNA (mRNA) therapeutics and vaccines worldwide. The company focuses on tackling a wide range of medical challenges, including infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases on a global scale. Moderna's diverse portfolio includes respiratory vaccines such as COVID-19, flu, and respiratory syncytial virus vaccines, as well as latent vaccines targeting cytomegalovirus, Epstein-Barr virus, and other viruses. Additionally, the company develops public health vaccines for diseases like Zika and Nipah.
Beyond vaccines, Moderna offers systemic secreted and cell surface therapeutics, cancer vaccines including personalized cancer and KRAS vaccines, and various immuno-oncology products designed for intratumoral use. The company also explores localized regenerative therapies, systemic intracellular therapeutics, and inhaled pulmonary treatments. Moderna collaborates extensively within the biopharmaceutical industry and has strategic alliances with prominent entities such as AstraZeneca PLC, Merck & Co., Vertex Pharmaceuticals, and the Bill & Melinda Gates Foundation. These collaborations underscore Moderna's commitment to advancing medical innovation through cutting-edge research and development.
Founded in 2010 as Moderna Therapeutics, Inc., the company rebranded as Moderna, Inc. in 2018. Moderna has rapidly emerged as a leader in mRNA technology, leveraging its scientific expertise to deliver transformative therapies and vaccines worldwide. With a robust pipeline and a strong emphasis on pioneering mRNA-based solutions, Moderna continues to expand its capabilities and partnerships, aiming to address critical healthcare needs and improve patient outcomes across diverse therapeutic areas.
Moderna stock FAQ
What is the Moderna stock ticker symbol?
Moderna, Inc. trades on the NASDAQ under the ticker symbol MRNA.
What sector and industry is Moderna in?
Moderna, Inc. is classified in the Healthcare sector, Biotechnology industry.
How many employees does Moderna have?
Moderna, Inc. has about 4,700 full-time employees.
What were Moderna's revenue and earnings last fiscal year?
Moderna reported revenue of $1.94B and net income of -$2.82B in fiscal 2025, with earnings per share of -$7.27. Revenue declined 39.2% from the prior year.
Is Moderna in the Nasdaq-100?
Yes. Moderna, Inc. (MRNA) is a component of the Nasdaq-100 index, which tracks the largest non-financial companies listed on the Nasdaq Stock Market.
Is Moderna in the S&P 500?
Yes. Moderna, Inc. (MRNA) is a component of the S&P 500, the index of 500 leading U.S. companies widely used as a benchmark for the U.S. stock market.
Is Moderna in the Russell 1000?
Yes. Moderna, Inc. (MRNA) is a component of the Russell 1000, which tracks roughly the 1,000 largest U.S. companies.
When did Moderna go public?
Moderna stock began trading on December 7, 2018.